832
Views
5
CrossRef citations to date
0
Altmetric
Original Articles: Research

NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines

, , , , , , , , & show all
Pages 3198-3206 | Received 09 Dec 2014, Accepted 22 Mar 2015, Published online: 12 May 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Carlos Cuesta-Mateos, Raquel Juárez-Sánchez, Tamara Mateu-Albero, Javier Loscertales, Wim Mol, Fernando Terrón & Cecilia Muñoz-Calleja. (2021) Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. mAbs 13:1.
Read now

Articles from other publishers (4)

Ida Franiak-Pietryga, Barbara Ziemba, Hanna Sikorska, Magdalena Jander, Wojciech Kuncman, Marian Danilewicz, Dietmar Appelhans, Przemyslaw Lewkowicz, Kinga Ostrowska, Maria Bryszewska & Maciej Borowiec. (2020) Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL. Toxicology and Applied Pharmacology 403, pages 115139.
Crossref
Barbara Ziemba, Hanna Sikorska, Magdalena Jander, Wojciech Kuncman, Marian Danilewicz, Dietmar Appelhans, Maria Bryszewska, Maciej Borowiec & Ida Franiak-Pietryga. (2020) Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia. Anti-Cancer Agents in Medicinal Chemistry 20:3, pages 325-334.
Crossref
Keshu Zhou, Wentao Zhang, Qing Zhang, Ruirui Gui, Huifang Zhao, Xiaofei Chai, Yufu Li, Xudong Wei & Yongping Song. (2017) Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia. Oncotarget 8:15, pages 25469-25481.
Crossref
Chelsey L. Patten & Christine E. Cutucache. (2016) Murine Models of Splenic Marginal Zone Lymphoma: A Role for Cav1?. Frontiers in Oncology 6.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.